Navigation Links
MedCath Corporation Reports Third Quarter Earnings
Date:8/5/2009

CHARLOTTE, N.C., Aug. 5 /PRNewswire-FirstCall/ -- MedCath Corporation (Nasdaq: MDTH), a healthcare provider focused on high acuity healthcare services, predominately the diagnosis and treatment of cardiovascular disease, today announced its operating results for its third quarter which ended June 30, 2009.

Highlights

  • A 6.1% increase in patient visits, including inpatient and outpatient cases, and emergency department visits, compared to the third quarter of fiscal 2008.
  • Operating cash flow from continuing operations of $18.7 million.
  • EPS from continuing operations of $0.03 or Adjusted EPS from continuing operations of $0.22, excluding pre-opening expense, stock-based compensation expense and other items.

Third Quarter 2009 Results

MedCath's reported net revenue decreased 2.2% to $150.9 million in the third quarter of fiscal 2009 from $154.3 million in the third quarter of fiscal 2008. Income from operations decreased to $2.2 million from $13.2 million in the third quarter of fiscal 2008 and Adjusted EBITDA decreased to $11.3 million from $22.7 million in the same period of the prior year. MedCath's income from continuing operations was $0.6 million, or $0.03 per diluted share, in the third quarter of fiscal 2009 compared to $4.9 million, or $0.25 per diluted share, in the third quarter of fiscal 2008.

"We continue to move forward on our transformation strategy by increasing capacity to diversify our Company's service offering," said Ed French, MedCath's President and Chief Executive Officer. "During the quarter, we completed expansion of our Louisiana Medical Center and Heart Hospital, adding 79 beds to the hospital's infrastructure, and we are on pace to open the Hualapai Mountain Medical Center in October. The addition of this new capacity will allow us to expand the population of patients that can benefit from our proven high-level of care. We are affirmed in our strategy to diversify and mitigate risk associated with single-product reliance as we have embarked upon our expansion investments."

MedCath's operating results for the third quarter of fiscal 2009 reflect the following items:

  • $2.7 million, or $0.08, net per diluted share of the decrease in net revenue and Adjusted EBITDA related to a reduction in the estimated amount of Medicare Disproportionate Share Hospital (DSH) payments certain hospitals were eligible for in prior fiscal years. The primary method for a hospital to qualify for Medicare DSH reimbursement is based on a statutory formula that utilizes the percentage of inpatient days attributable to patients eligible for Medicaid, but not eligible for Medicare Part A, and a base formula called the Supplemental Security Income (SSI) percentage, which is released annually by the Centers for Medicare and Medicaid Services (CMS). Based on the updated SSI percentage provided by CMS in June 2009, MedCath has determined that four hospitals that were previously determined to be eligible for DSH payments in fiscal 2007 and fiscal 2008 would either no longer be eligible for such payments or would be eligible for less payment than initially estimated.
  • $0.4 million, or $0.01, net per diluted share of the decrease in Adjusted EBITDA related to the reduction in the estimated amount of charges eligible for Medicaid reimbursement from fiscal 2004 to 2006, which resulted in an updated cost to charge ratio at one of our hospitals.
  • $1.1 million, or $0.03, net per diluted share, of the decrease in Adjusted EBITDA related to professional fees associated with an internal assessment of certain controls and procedures completed during the quarter.
  • $0.8 million, or net impact of $0.03, net per diluted share of the decrease in Adjusted EBITDA reflects the anticipated settlement of Medicare claims at two of our hospitals related to the identification, return and self-reporting of $0.7 million in reimbursement for certain procedures performed at the two hospitals in prior fiscal years.
  • $0.4 million, or $0.01 net per diluted share, of the decrease in Adjusted EBITDA related to severance expense.

Adjusted EBITDA excludes share-based compensation and pre-opening expenses, but these items are included as a component of income from continuing operations. Share-based compensation expense totaled $0.2 million in the third quarter of fiscal 2009, or $0.01 per diluted share, compared to a $1.5 million expense, or $0.05 per diluted share, in the third quarter of fiscal 2008. Pre-opening expenses totaled $0.8 million in the third quarter of fiscal 2009, or $0.02 per diluted share, compared to $0.1 million in the third quarter of fiscal 2008.

Operating Statistics, Cash Flow and Capital Expenditures

Same facility hospital admissions in the third quarter of fiscal 2009 were 6,352, down 14.0% compared with the third quarter of fiscal 2008. Adjusted admissions totaled 10,284, in line with the third quarter of fiscal 2008. Same facility hospital outpatient cases totaled 8,866 in the third quarter of fiscal 2009, up 15.7% in comparison with the third quarter of fiscal 2008.

Total uncompensated care, which includes charity care plus bad debt expense, equaled 9.3% of hospital division net patient revenue before the deduction for charity care in the third quarter of fiscal 2009 and the third quarter of fiscal 2008.

Net cash provided by operating activities of continuing operations for the third quarter of fiscal 2009 was $18.7 million compared to $18.9 million in the third quarter of fiscal 2008. Cash paid for capital expenditures during the quarter totaled $18.6 million, which included $4.8 million related to maintenance expenditures and $13.8 million related to MedCath's construction projects.

Use of Non-GAAP Financial Measures

Included in this press release and the supplemental financial information furnished herewith are certain financial measures that are not generally accepted accounting principles ("non-GAAP"), such as Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") and Adjusted diluted earnings per share from continuing operations ("Adjusted EPS"). Adjusted EBITDA represents MedCath's income from continuing operations before interest expense; loss on early extinguishment of debt; income tax expense; depreciation; amortization; share-based compensation expense; (gain) loss on disposal of property, equipment and other assets; interest and other income; equity in net earnings of unconsolidated affiliates; minority interest share of earnings of consolidated subsidiaries; and pre-opening expenses. Adjusted EPS represents MedCath's diluted earnings per share from continuing operations for the three months ended June 30, 2009 adjusted for Medicare Disproportionate Share Hospital ("DSH") adjustments, reduction in Medicaid reimbursements, professional fees for an internal control assessment, settlement of Medicare claims, severance expense, share-based compensation, and pre-opening expenses. MedCath's management uses Adjusted EBITDA to measure the performance of MedCath's various operating entities, to compare actual results to historical and budgeted results, and to make capital allocation decisions. Management provides Adjusted EBITDA and Adjusted EPS to investors to assist them in performing their analyses of MedCath's historical operating results. Further, management believes that many investors in MedCath also invest in, or have knowledge of, other healthcare companies that use Adjusted EBITDA and/or Adjusted EPS as a financial performance measure.

Because Adjusted EBITDA and Adjusted EPS are non-GAAP measures, Adjusted EBITDA and Adjusted EPS, as defined above, may not be comparable to other similarly titled measures of other companies. MedCath has included a supplemental schedule with the financial statements that accompanies this press release that reconciles historical Adjusted EBITDA to MedCath's income from continuing operations and Adjusted EPS to diluted EPS from continuing operations.

Management will discuss and answer questions regarding MedCath's quarterly results on Thursday, August 6, 2009, during a 10 a.m. ET conference call. In the United States, you may participate by dialing (877) 697-5351. International callers should dial (706) 634-0602. The conference ID for both domestic and international callers is 21652039. A live web cast will also be available on the company's web site, www.medcath.com. This information will be available on the web site on or immediately following the conference call for 30 days. A recorded replay of the call will be available until 11:59 p.m. ET, August 20, 2009. To access the replay, domestic callers should dial (800) 642-1687 and international callers should dial (706) 645-9291. The archived conference ID is 21652039. This press release and the financial information included therewith will be accessible on the web, by going to www.medcath.com, "Investor Relations," then clicking on "News."

MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns an interest in and operates nine hospitals with a total of 755 licensed beds, located in Arizona, Arkansas, California, Louisiana, New Mexico, South Dakota, and Texas. MedCath is in the process of developing its tenth hospital, which is anticipated to open in fall 2009, in Kingman, Ariz. In addition, MedCath and its subsidiary MedCath Partners provide services in diagnostic and therapeutic facilities in various states.

Parts of this announcement contain forward-looking statements that involve risks and uncertainties. Although management believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic, regulatory and competitive uncertainties and contingencies that are difficult or impossible to predict accurately and are beyond our control including, but not limited to, enactment of changes in federal law that would limit physician hospital ownership. Actual results could differ materially from those projected in these forward-looking statements. We do not assume any obligation to update these statements in a news release or otherwise should material facts or circumstances change in ways that would affect their accuracy. The preparation of MedCath's third quarter operating results required management to make estimates and assumptions that affect reported amounts of revenues and expenses. There is a reasonable possibility that actual results may vary significantly from those estimates.

These various risks and uncertainties are described in detail in "Risk Factors" in MedCath's Annual Report or Form 10-K for the year ended September 30, 2008 filed with the Securities and Exchange Commission on December 15, 2008, as updated in our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009. Copies of our filings with the Securities and Exchange Commission, including exhibits, are available at http://www.sec.gov.

                                 MEDCATH CORPORATION
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                        (In thousands, except per share data)
                                     (Unaudited)

                                       Three Months Ended   Nine Months Ended
                                             June 30,            June 30,
                                             --------            --------
                                           2009      2008      2009      2008
                                           ----      ----      ----      ----

      Net revenue                      $150,904  $154,273  $462,874  $455,168
      Operating expenses:
        Personnel expense                50,862    50,520   153,644   150,060
        Medical supplies expense         44,995    42,757   131,457   123,155
        Bad debt expense                 12,547    10,235    34,558    31,852
        Other operating expenses         31,441    29,555    96,022    88,996
        Pre-opening expenses                754       149     1,340       643
        Depreciation                      7,858     7,505    23,258    22,535
        Amortization                        230       149       589       411
        (Gain) loss on disposal of
         property, equipment and
         other assets                       (26)      225       138       391
                                            ---       ---       ---       ---
          Total operating expenses      148,661   141,095   441,006   418,043
                                        -------   -------   -------   -------
      Income from operations              2,243    13,178    21,868    37,125
      Other income (expenses):
        Interest expense                 (1,151)   (3,862)   (5,339)  (11,658)
        Loss on early extinguishment
         of debt                              -         -    (6,702)        -
        Interest and other income            52       284       218     1,930
        Equity in net earnings of
         unconsolidated affiliates        2,265     2,636     7,044     6,842
                                          -----     -----     -----     -----
          Total other income
           (expense), net                 1,166      (942)   (4,779)   (2,886)
                                          -----      ----    ------    ------
      Income from continuing operations
       before minority interest and
       income taxes                       3,409    12,236    17,089    34,239
      Minority interest share of
       earnings of consolidated
       subsidiaries                      (2,287)   (3,865)   (9,703)  (12,644)
                                         ------    ------    ------   -------
      Income from continuing
       operations before income taxes     1,122     8,371     7,386    21,595
      Income tax expense                    536     3,469     2,998     8,917
                                            ---     -----     -----     -----
      Income from continuing
       operations                           586     4,902     4,388    12,678
      (Loss) income from discontinued
       operations, net of taxes             (90)    6,870     3,936     7,843
                                            ---     -----     -----     -----
      Net income                           $496   $11,772    $8,324   $20,521
                                           ====   =======    ======   =======

      Earnings per share, basic
         Continuing operations            $0.03     $0.25     $0.22     $0.62
         Discontinued operations          (0.00)     0.35      0.20      0.38
                                          -----      ----      ----      ----
         Earnings per share, basic        $0.03     $0.60     $0.42     $1.00
                                          -----     -----     -----     -----

      Earnings per share, diluted
         Continuing operations            $0.03     $0.25     $0.22     $0.62
         Discontinued operations          (0.00)     0.35      0.20      0.38
                                          -----      ----      ----      ----
         Earnings per share, diluted      $0.03     $0.60     $0.42     $1.00
                                          -----     -----     -----     -----

      Weighted average number of
       shares, basic                     19,733    19,524    19,665    20,415
      Dilutive effect of stock
       options and restricted stock           -       107        56        89
                                            ---       ---       ---       ---
      Weighted average number of
      shares, diluted                    19,733    19,631    19,721    20,504
                                         ======    ======    ======    ======


                                  MEDCATH CORPORATION
                              CONSOLIDATED BALANCE SHEETS
                           (In thousands, except share data)

                                                     June 30,   September 30,
                                                       2009           2008
                                                       ----           ----
                                                   (Unaudited)

      Current assets:
        Cash and cash equivalents                     $42,857        $93,836
        Restricted cash                                 3,166          3,154
        Accounts receivable, net                       76,205         83,875
        Income tax receivable, net                      3,940          3,091
        Medical supplies                               18,335         15,479
        Deferred income tax assets                      7,600          9,769
        Prepaid expenses and other current assets      12,235          9,796
        Current assets of discontinued operations      10,052         20,776
                                                       ------         ------
          Total current assets                        174,390        239,776
      Property and equipment, net                     370,418        323,729
      Investments in affiliates                        13,261         15,285
      Goodwill                                         60,174         60,174
      Other intangible assets, net                      5,974          6,063
      Other assets                                     13,167          8,378
      Long-term assets of discontinued operations           -             51
                                                          ---            ---
        Total assets                                 $637,384       $653,456
                                                     ========       ========

      Current liabilities:
        Accounts payable                              $40,613        $41,642
        Accrued compensation and benefits              17,980         16,872
        Other accrued liabilities                      25,793         24,054
        Current portion of long-term debt and
         obligations under capital leases              19,133         31,920
        Current liabilities of discontinued
         operations                                     9,560         10,184
                                                        -----         ------
          Total current liabilities                   113,079        124,672
      Long-term debt                                  104,683        115,628
      Obligations under capital leases                  4,111          2,087
      Deferred income tax liabilities                  12,267         12,352
      Other long-term obligations                       6,882          4,454
                                                        -----          -----
          Total liabilities                           241,022        259,193

      Minority interest in equity
       of consolidated subsidiaries                    18,737         24,667

      Stockholders' equity:
        Preferred stock, $0.01 par value,
         10,000,000 shares authorized;
         none issued                                        -              -
        Common stock, $0.01 par value,
         50,000,000 shares authorized;
         21,691,780 issued and 19,737,419
         outstanding at June 30, 2009;
         21,553,054 issued and 19,598,693
         outstanding at September 30, 2008                216            216
        Paid-in capital                               455,346        455,494
        Accumulated deficit                           (32,814)       (41,138)
        Accumulated other comprehensive loss             (326)          (179)
        Treasury stock, at cost;
        1,954,361 shares at June 30, 2009
        1,954,361 shares at September 30, 2008        (44,797)       (44,797)
                                                      -------        -------
          Total stockholders' equity                  377,625        369,596
                                                      -------        -------
          Total liabilities and stockholders'
           equity                                    $637,384       $653,456
                                                     ========       ========


                                  MEDCATH CORPORATION
                                SELECTED OPERATING DATA
           (In thousands, except per share data and selected operating data)
                                      (Unaudited)
                         Three Months Ended            Nine Months Ended
                              June 30,                      June 30,
                              --------                      --------
                         2009      2008  % Change    2009      2008  % Change
                         ----      ----  --------    ----      ----  --------

    Statement of
     Operations Data:
    Net revenue      $150,904  $154,273    (2.2)% $462,874  $455,168     1.7%
    Adjusted
     EBITDA (1)       $11,290   $22,747   (50.4)%  $49,261   $66,568   (26.0)%
    Income from
     operations        $2,243   $13,178   (83.0)%  $21,868   $37,125   (41.1)%
    Income from
     continuing
     operations          $586    $4,902   (88.0)%   $4,388   $12,678   (65.4)%
    Earnings per
     share from
     continuing
     operations,
     basic              $0.03     $0.25   (88.0)%    $0.22     $0.62   (64.5)%
    Earnings per
     share from
     continuing
     operations,
     diluted            $0.03     $0.25   (88.0)%    $0.22     $0.62  (64.5)%

    (1) See Supplemental Financial Disclosure--Reconciliation of GAAP
        Financial Measures to Non-GAAP Financial Measures.


                         Three Months Ended            Nine Months Ended
                              June 30,                      June 30,
                              --------                      --------
                         2009      2008  % Change      2009    2008  % Change
                         ----      ----  --------      ----    ----  --------
    Selected Operating
     Data (a):
    Number of
     hospitals              7         7                  7         7
    Licensed
     beds ( c )           588       449                588       449
    Staffed and
     available
     beds ( d )           542       449                542       449
    Admissions ( e )    6,352     7,384   (14.0)%   20,152    22,380   (10.0)%
    Adjusted
     admissions ( f )  10,284    10,341    (0.6)%   30,714    30,979    (0.9)%
    Patient
     days ( g )        25,482    27,132    (6.1)%   78,681    81,853    (3.9)%
    Adjusted
     patient
     days ( h )        41,174    38,105     8.1%   120,106   113,790     5.6%
    Average length
     of stay (days)
     ( i )               4.01      3.67     9.3%      3.90      3.66     6.6%
    Occupancy ( j )      51.7%     66.4%              53.2%     66.5%
    Inpatient
     catheterization
      procedures ( k )  3,071     3,961   (22.5)%   10,069    12,244   (17.8)%
    Inpatient
     Surgical
    procedures ( l )    2,045     2,260    (9.5)%    6,133     6,332    (3.1)%
    Hospital net
     revenue         $141,665  $144,676    (2.1)% $436,457  $426,300     2.4%

    Combined Operating
     Data (b):
    Number of
     hospitals             9         9                  9         9
    Licensed
     beds ( c )          755       676                755       676
    Staffed and
    available beds
    ( d )                705       612                705       612
    Admissions ( e )    9,187     9,879    (7.0)%   28,917    30,179    (4.2)%
    Adjusted
    admissions ( f )   14,979    14,512     3.2%    44,849    43,838     2.3%
    Patient
     days ( g )        33,885    34,819    (2.7)%  105,350   106,614    (1.2)%
    Adjusted
    patient
    days ( h )         54,810    50,722     8.1%   162,387   153,697     5.7%
    Average length
    of stay (days)
    ( i )               3.69      3.52     4.8%      3.64      3.53     3.1%
    Occupancy ( j )     52.8%     62.5%              54.7%     63.6%
    Inpatient
    catheterization
     procedures ( k )  3,786     4,814   (21.4)%   12,427    14,624   (15.0)%
    Inpatient
     surgical
     procedures ( l )  2,618     2,842    (7.9)%    7,951     8,287    (4.1)%
    Hospital net
     revenue        $182,058  $183,446    (0.8)% $558,548  $545,892     2.3%


    ( a ) Selected operating data includes consolidated hospitals in operation
          as of the end of the period reported in continuing operations but
          does not include hospitals which are accounted for using the equity
          method or as discontinued operations in our consolidated financial
          statements.
    ( b ) Combined operating data includes hospitals in operation as of the
          End of the period reported in continuing operations including
          hospitals which are accounted for using the equity method in our
          consolidated financial statements.
    ( c ) Licensed beds represent the number of beds for which the appropriate
          state agency licenses a facility regardless of whether the beds are
          actually available for patient use.
    ( d ) Staffed and available beds represent the number of beds that are
          readily available for patient use at the end of the period.
    ( e ) Admissions represent the number of patients admitted for inpatient
          treatment.
    ( f ) Adjusted admissions is a general measure of combined inpatient and
          outpatient volume.  We computed adjusted admissions by dividing
          gross patient revenue by gross inpatient revenue and then
          multiplying the quotient by admissions.
    ( g ) Patient days represent the total number of days of care provided
          to inpatients.
    ( h ) Adjusted patient days is a general measure of combined inpatient
          and outpatient volume.  We computed adjusted patient days by
          dividing gross patient revenue by gross inpatient revenue and
          then multiplying the quotient by patient days.
    ( i ) Average length of stay (days) represents the average number of
          days inpatients stay in our hospitals.
    ( j ) We computed occupancy by dividing patient days by the number of
          days in the period and then dividing the quotient by the number
          of staffed and available beds.
    ( k ) Inpatients with a catheterization procedure represent the number
          of inpatients with a procedure performed in one of the hospitals'
          catheterization labs during the period.
    ( l ) Inpatient surgical procedures represent the number of surgical
          procedures performed on inpatients during the period.



                       MEDCATH CORPORATION
     SUPPLEMENTAL FINANCIAL DISCLOSURE - RECONCILIATION OF GAAP FINANCIAL
                      MEASURES TO NON-GAAP FINANCIAL MEASURES
                           (Unaudited)



    The following table reconciles Adjusted EBITDA with MedCath's income
    from continuing operations as derived directly from MedCath's
    consolidated financial statements for the three and nine months ended
    June 30, 2009 and 2008.


                                         Three Months       Nine Months
                                         Ended June 30,     Ended June 30,
                                         --------------     -------------
                                          2009     2008     2009     2008
                                          ----     ----     ----     ----
                                         (in thousands)    (in thousands)

    Income from continuing
     operations                           $586   $4,902   $4,388  $12,678
    Add:
      Income tax expense                   536    3,469    2,998    8,917
      Minority interest share of
       earnings of consolidated
       subsidiaries                      2,287    3,865    9,703   12,644
      Equity in net earnings of
       unconsolidated affiliates        (2,265)  (2,636)  (7,044)  (6,842)
      Interest and other income            (52)    (284)    (218)  (1,930)
      Loss on early extinguishment
       of debt                               -        -    6,702        -
      Interest expense                   1,151    3,862    5,339   11,658
      (Gain) loss on disposal of
       property, equipment and
       other assets                        (26)     225      138      391
      Amortization                         230      149      589      411
      Depreciation                       7,858    7,505   23,258   22,535
      Pre-opening expenses                 754      149    1,340      643
      Share-based compensation
       expense                             231    1,541    2,068    5,463
                                           ---    -----    -----    -----
    Adjusted EBITDA                    $11,290  $22,747  $49,261  $66,568
                                       =======  =======  =======  =======


    The following table reconciles adjusted diluted earnings per share from
    continuing operations with MedCath's diluted earnings share from
    continuing operations as derived directly from MedCath's consolidated
    financial statements for the three months ended June 30, 2009.



    Diluted earnings per share           $0.03
    Add:
      DSH adjustments                     0.08
      Medicaid reimbursement charges      0.01
      Professional fees for internal
       assessment                         0.03
      Settlement of Medicare claims       0.03
      Severance expense                   0.01
      Share-based compensation expense    0.01
      Pre-opening expense                 0.02
                                          ----
    Adjusted diluted earnings per share  $0.22
                                         =====




'/>"/>
SOURCE MedCath Corporation
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
2. MedCath Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
3. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
4. MedCath Corporation to Hold Conference Call on First Quarter Results
5. MedCath Corporation Reports First Quarter Earnings
6. MedCath Plans 60-bed Expansion at TexSAn Heart Hospital
7. MedCath Announces Venture With Two New Jersey Hospitals
8. MedCath Corporation to Present at the Raymond James 29th Annual Institutional Investors Conference
9. MedCath Corporation to Present at the Citi 2008 Small and Mid-Cap Conference
10. MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton
11. MedCath Announces Acquisition of Ownership in Arizona Cath Lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information to ... combines three elements to cut the cost of providing employee healthcare benefits by ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)...  Patients in Alabama seeking prostate ... no longer have to travel out of state. Vituro ... Urology Centers of Alabama to provide a total prostate ... patients. Alabama is known ... prostate cancer using many different modalities. They are the largest ...
(Date:2/5/2016)...  Venice,s newest laser clinic, Physicians Advanced ... kind in the area and specializes in the ... The physician-owned and operated laser clinic is taking ... with its revitalizing skin care approach, unprecedented eVisit ... technology. http://photos.prnewswire.com/prnh/20160204/329957 --> ...
(Date:2/5/2016)... --> --> ... (Labor & Delivery) and Neonatal Care Equipment Market Ultrasound, ... Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - Global ... the global market over the forecast period of 2015 ... Billion in 2015 and is poised to grow at ...
Breaking Medicine Technology: